Solmi M, Tiihonen J, Lähteenvuo M, et al. - In view of the observation that early mortality among people with schizophrenia/schizoaffective disorder (schizophrenia) is largely due to cardiovascular-related mortality and antipsychotics are linked with lower mortality, researchers sought to determine if antipsychotic use can lower discontinuation of medications for cardiovascular risk factors and diseases (“cardiometacolic drugs”), using a within-study design controlling for subject-related factors. Finnish national databases were searched for persons diagnosed with schizophrenia between 1972 and 2014, aged <65 years at cohort entry. Based on cardiometabolic drug use during the follow-up period, they formed four subcohorts, 1996–2017, namely statin (n = 14,047), antidiabetic (n = 13,070), antihypertensive (n = 17,227), and beta-blocker (n = 21,464) users. In this national database within-subject design study, substantially reduced risk of discontinuation of statins, anti-diabetics, antihypertensives, and beta-blockers was observed in correlation with current antipsychotic use; this might explain decreased cardiovascular mortality seen with antipsychotics in people with schizophrenia.